Viridian Therapeutics (NASDAQ:VRDN) versus ACI Global (OTCMKTS:ACGJ) Financial Analysis

Viridian Therapeutics (NASDAQ:VRDN) and ACI Global (OTCMKTS:ACGJ) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Profitability

This table compares Viridian Therapeutics and ACI Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-85,127.16%	-70.12%	-41.49%
ACI Global	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings for Viridian Therapeutics and ACI Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	0	3	9	0	2.75
ACI Global	0	0	0	0	0.00

Viridian Therapeutics presently has a consensus price target of $35.70, suggesting a potential upside of 147.23%. Given Viridian Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than ACI Global.

Earnings and Valuation

This table compares Viridian Therapeutics and ACI Global”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$302,000.00	3,896.17	-$237.73 million	($3.77)	-3.83
ACI Global	N/A	N/A	N/A	N/A	N/A

ACI Global has lower revenue, but higher earnings than Viridian Therapeutics.

Volatility and Risk

Viridian Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, ACI Global has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

About ACI Global

ACI Global Corporation, a development stage company, through its subsidiaries, engages in the design and development of proprietary technology for the production of synthetic rubber powder and thermoplastic elastomers under Micropowder trade name in the United States. It intends to utilize Micropowder technology in its chemical composition and for the manufacture of rubber and elastomers that are used in tire plastic industries. ACI Global was founded in 1997 and is based in Greenwich, Connecticut.